Is rosiglitazone associated with increased risk for cardiovascular events?

摘要

This was a meta-analysis of publicly available data, including both studies submitted to the FDA before the approval of rosiglitazone, and trials carried out after the drug was licensed. Trials were included in the analysis if they were randomized and compared rosiglitazone with placebo or an alternative antidiabetic drug, if patients received at least 24 weeks of therapy, and if the duration of treatment was similar in the rosiglitazone and control groups. Studies that reported no cardiovascular events in either treatment group were excluded. Odds ratios were calculated using the Peto method.